Evidence map›Paper›PMID 26015865›Full record

ArticleVascular cell2015

Solenopsin A and analogs exhibit ceramide-like biological activity.

Isabella Karlsson, Xin Zhou, Raquela Thomas, Allorie T Smith, Michael Y Bonner, Pooja Bakshi, Ajay K Banga, J Phillip Bowen, Ghassan Qabaja, Shavon L Ford and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Vascular cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Therapeutic Potential ofBiomolecules · 2024
    Article
  5. Potential anti-tumor effects ofFrontiers in immunology · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Isabella KarlssonDepartment of Dermatology, Emory University School of Medicine, Atlanta, GA USA.
Xin ZhouDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD USA.
Raquela ThomasDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC USA.
Allorie T SmithDepartment of Pharmaceutical Sciences, School of Pharmacy, Union University, Jackson, TN USA.
Michael Y BonnerDepartment of Dermatology, Emory University School of Medicine, Atlanta, GA USA.
Pooja BakshiCenter for Drug Design, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA USA.
Ajay K BangaCenter for Drug Design, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA USA.
J Phillip BowenCenter for Drug Design, Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA USA.
Ghassan QabajaDepartment of Chemistry & Biochemistry, University of North Carolina Greensboro, Greensboro, NC USA.
Shavon L FordDepartment of Chemistry & Biochemistry, University of North Carolina Greensboro, Greensboro, NC USA.
Matthew D BallardDepartment of Chemistry & Biochemistry, University of North Carolina Greensboro, Greensboro, NC USA.
Kimberly S PetersenDepartment of Chemistry & Biochemistry, University of North Carolina Greensboro, Greensboro, NC USA.
Xuechen LiDepartment of Physiology and Renal Division, Emory University School of Medicine, Atlanta, GA USA.
Guangping ChenDepartment of Physiology and Renal Division, Emory University School of Medicine, Atlanta, GA USA.
Besim OgretmenDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC USA.
Jin ZhangDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD USA.
E Blake WatkinsDepartment of Pharmaceutical Sciences, School of Pharmacy, Union University, Jackson, TN USA.
Rebecca S ArnoldDepartment of Urology, Emory University School of Medicine, Atlanta, GA USA.
Jack L ArbiserDepartment of Dermatology, Emory University School of Medicine, Atlanta, GA USA ; Atlanta Veterans Administration Hospital, and Winship Cancer Institute, Emory University, Atlanta, GA USA.
Emory University · USUniversity of North Carolina at Greensboro · USMercer University · USMedical University of South Carolina · USUnion University · USJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

Mechanisms of Compartmentalized cAMP SignalingR01DK073368 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jin Zhang · 2006 to 2026
$7.6M
MUSC Minority Student Development ProgramR25GM072643 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE, RINKER, JENNIFER ANNE · 2005 to 2023
$5.8M
Cutaneous Hemangiomas and Signal TransductionR01AR047901 · NIAMS · EMORY UNIVERSITY · PI ARBISER, JACK L · 2001 to 2018
$4.3M
NIAMS NIH HHS R01 AR047901NIDDK NIH HHS R01 DK073368NIGMS NIH HHS R25 GM072643
6 · The paper itself

Abstract

background(-)-Solenopsin A is a piperidine alkaloid that is a component of the venom of the fire ant Solenopsis invicta. Previously, we have demonstrated that solenopsin exhibit anti-angiogenic activity and downregulate phosphoinositol-3 kinase (PI3K) in the p53 deficient renal cell carcinoma cell line 786-O. Solenopsin has structural similarities to ceramide, a major endogenous regulator of cell signaling and cancer therapy induced apoptosis.

methodsDifferent analogs of solenopsin were synthesized in order to explore structure-activity relationships. The anti-proliferative effect of solenopsin and analogs was tested on six different cell lines, including three tumor cell lines, two normal cutaneous cell lines, and one immortalized hyperproliferative cell line. FRET-based reporters were used to study the affect of solenopsin and analogs on Akt activity and PDK1 activation and sucrose density gradient fractionation was performed to examine recruitment of PTEN to membrane rafts. Western-blotting was used to evaluate the affect of solenopsin and analogs on the Akt and the MAPK 44/42 pathways in three different tumor cell lines. Measurement of cellular oxygen consumption rate together with autophagy staining was performed to study mitochondrial function. Finally, the affect of solenopsin and analogs on ROS production was investigated.

resultsIn this paper we demonstrate that solenopsin analogs with potent anti-proliferative effects can be synthesized from inexpensive dimethylpyridines. To determine whether solenopsin and analogs act as ceramide analogs, we examined the effect of solenopsin and analogs on two stereotypic sites of ceramide activity, namely at lipid rafts and mitochondria. We found that native solenopsin, (-)-solenopsin A, inhibits functional Akt activity and PDK1 activation in lipid rafts in a similar fashion as ceramide. Both cis and trans analogs of solenopsin reduce mitochondrial oxygen consumption, increase reactive oxygen, and kill tumor cells with elevated levels of Akt phosphorylation. However, only solenopsin induces mitophagy, like ceramide.

conclusionsThe requirements for ceramide induced mitophagy and inhibition of Akt activity and PDK1 activation in lipid rafts are under strict stereochemical control. The naturally occurring (-)-solenopsin A mimic some of the functions of ceramide and may be therapeutically useful in the treatment of hyperproliferative and malignant disorders of the skin, even in the presence of elevated levels of Akt.

Indexed as

AktCeramideMitophagyReactive oxygenSolenopsin A

Identifiers

PMID26015865
PMCPMC4443652
OpenAlexW2145059132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.